Oct 2026· Journal of Molecular Graphics and Modelling· Vol 150, pp.
109625
· 0 citations· 30 references
Medicine
TL;DR
This integrative computational framework combines proteome-scale target discovery, pathway prioritization, structural validation, molecular dynamics, and ADMET evaluation to provide a systems-level perspective on the potential multi-target anticancer mechanisms of anthraquinone derivatives and identify candidate targets for future experimental validation.
Abstract
Cancer is a multifactorial and heterogeneous disease in which single-target therapeutic strategies often fail to achieve sustained efficacy. Anthraquinone derivatives exhibit diverse anticancer activities; however, their comprehensive molecular targets and mechanisms of action remain incompletely characterized. In this study, a proteome-wide reverse virtual screening strategy was applied to identify potential human protein targets of five sugar-free anthraquinone derivatives, including emodin, chrysophanol, aloe-emodin, physcion, and rhein. 67,000 human protein structures were screened using AutoDock Vina, followed by binding energy-based filtering and removal of redundant targets, resulting in 123 non-redundant proteins. Functional annotation and pathway analysis revealed cancer-associated biological processes linked to the identified targets. Comparative pathway analysis identified 64 overlapping pathways, from which 10 key pathways and six core protein targets were prioritized based on multi-ligand convergence. Predicted binding affinities of the retained ligand-target combinations for the prioritized targets ranged from -9.0 to -10.7 kcal/mol, with emodin and chrysophanol showing comparatively stronger binding affinities. LigPlot + analysis characterized hydrogen-bonding and hydrophobic interactions involved in ligand stabilization. Furthermore, 100 ns molecular dynamics simulations showed that 19 of the 27 simulated ligand-protein complexes retained the predicted binding mode, while the remainder underwent partial or complete ligand dissociation, and in silico ADMET analysis indicated acceptable drug-like properties and pharmacokinetic profiles. Overall, this integrative computational framework combines proteome-scale target discovery, pathway prioritization, structural validation, molecular dynamics, and ADMET evaluation to provide a systems-level perspective on the potential multi-target anticancer mechanisms of anthraquinone derivatives and identify candidate targets for future experimental validation.
Lung and breast cancers are among the major causes of cancer-related morbidity and mortality worldwide. Both these cancers share several dysregulated molecular processes, including common oncogenic signaling pathways and molecular targets. Therefore, the current study focuses on the dual anticancer potential of Annona...
S. Patil, A. Das, K. Asgaonkar et al.· Computers in Biology and Med...· 0 citations
Background: Tumour hypoxia is a critical hallmark of cancer progression, contributing to metastasis, therapeutic resistance, and poor clinical outcomes. Hypoxia-inducible factor-1 alpha (HIF-1α) regulates cellular adaptation to hypoxia by modulating angiogenesis, metabolism, and survival. Targeting HIF-1α represents a...
P. Tej, K. Nitya, S. Sundar et al.· Journal of Natural Remedies· 0 citations
By shifting from a "one-target, one-drug" model to a systems-level approach, the proposed MTDL and its natural analogs represent promising candidates for experimental validation in the treatment of complex, obesity-associated CRC.
Merve Uça Apaydın, Huseyin Guner, Resat Unal et al.· Cukurova Medical Journal· 0 citations
Results indicate that perimidine-based molecules, particularly Compound 101 and Compound 201, are promising compounds towards the development as EGFR-targeting anticancer drugs; however, further biochemical and cellular target-validation studies are required to confirm direct EGFR inhibition and their therapeutic poten...
M. Gopinadh, Sreehari A. P., S. S et al.· Naunyn-Schmiedeberg's Archiv...· 0 citations
Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality, and treatment efficacy is frequently limited by acquired resistance and systemic toxicity. Glutathione-responsive abasic site-trapping prodrugs have shown selective anticancer activity in prior experimental studies, but whether their...
Xian-Jun Wang, Zhi-Bo Peng, Yan-Chao Xing et al.· Journal of Visualized Experi...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.